Search the Newsreel

Relay Therapeutics (NASDAQ:RLAY) Stock Price Expected to Rise, HC Wainwright Analyst Says

HC Wainwright has increased its price target for Relay Therapeutics (NASDAQ:RLAY) to $29 from $28, maintaining a "buy" rating and projecting a 39.8% upside. Despite a recent quarterly loss of $0.41 per share and revenue below estimates, analyst sentiment remains largely positive, with a …

H.C. Wainwright reiterates Seaport Therapeutics stock rating at buy By Investing.com

H.C. Wainwright has reiterated a Buy rating for Seaport Therapeutics (NASDAQ:SPTX) with a $50.00 price target. The firm highlighted that the positive clinical data from a competitor's candidate could reduce competitive pressure for Seaport's GlyphAllo, and their non-hallucinogenic psychedelic candidate, Glyph2BLSD, could offer a …

Seaport Therapeutics' (SPTX) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright has reaffirmed its "Buy" rating for Seaport Therapeutics (SPTX), setting a $50 price target, which suggests a 104.75% upside. Despite this, analyst sentiment remains mixed, leading to a consensus "Hold" rating with an average target of $38.40. The company recently reported a …

Cardinal Health CEO, GMPD segment Mason sells $8.27m shares

Stephen M. Mason, CEO of GMPD Segment at Cardinal Health Inc., sold 35,000 common shares for approximately $8.27 million on August 18, 2026. This transaction involved shares sold at weighted average prices between $234.59 and $237.26, leaving him with 18,061 shares. The sale follows …

La directora jurídica de Cardinal Health, Jessica Mayer, vende acciones por 6.950 millones de dólares

Atlantic Lithium (LSE:ALL) Puts Lithium Stocks Under An Earnings-Quality Spotlight

UBS Adjusts J.M. Smucker Price Target to $142 From $130, Maintains Buy Rating

UBS has increased its price target for J.M. Smucker (SJM) to $142 from $130, while reiterating a Buy rating on the stock. This adjustment reflects an updated outlook from the analyst firm. Other firms like TD Cowen, Jefferies, Deutsche Bank, and JPMorgan have also …

FDA grants Fast Track designation to inhaled treatment for lung disease with 3-to-5-year median survival

Rein Therapeutics (NASDAQ: RNTX) announced that its lead candidate, LTI-03, an inhaled peptide for idiopathic pulmonary fibrosis (IPF), has received Fast Track designation from the U.S. FDA. This designation aims to expedite development and review for serious conditions with unmet medical needs. The company …

From Land Securities Group (LSE:LAND) To Renewables Infrastructure Group (LSE:TRIG): What Is Separating Infra and Real Estate Stocks Today?

A.O. Smith stock jumps as investors digest recent gains and valuation

A.O. Smith Corp. stock saw a significant 4.83% jump on August 19, 2026, closing at $63.80 with strong trading volume, indicating renewed investor interest. This surge places the stock above previous consolidation zones, suggesting investors are willing to pay a higher multiple based on …

From Hikma Pharmaceuticals (LSE:HIK) To Spire Healthcare Group (LSE:SPI): What Is Separating Healthcare Stocks Today?

Is Southwest Airlines (LUV) Stock Fairly Valued After A 40% Run?

Southwest Airlines (LUV) stock has seen a 40% return over the past three years, with a 35.3% return in the last year. Despite this strong performance, its current valuation, indicated by a P/E ratio of 24.2x (higher than the industry average), suggests it may …

Ithaca Energy Raises Dividend Guidance Despite Rosebank's Tightened Timeline

Monolithic (MPWR) Financial Update: Reported EPS Tops Expectations in the Latest Reading; Post-Earnings: Shares Fall 2.48% for the Current Session - Book Value Growth

Motor & General Finance Ltd. Revenue Breakdown – NSE:MOTOGENFIN

Zevra Therapeutics (NASDAQ:ZVRA) Receives "Buy" Rating from HC Wainwright

HC Wainwright has reiterated a "Buy" rating for Zevra Therapeutics (NASDAQ:ZVRA) with a $26 price target, suggesting a significant upside. This positive outlook is echoed by other analysts, resulting in a consensus "Moderate Buy" rating and an average target price of $27.14. The company …

Radiopharm advances RAD202 trial to higher dose level By Investing.com

Radiopharm Theranostics has received approval from its Data Safety and Monitoring Committee to increase the dose level of its RAD202 radiotherapeutic to 180mCi in a Phase 1 clinical trial. The trial, named HEAT, is evaluating 177Lu-RAD202 in patients with HER2-positive advanced solid tumors. This …

Is National Health Investors (NHI) Undervalued After Its Earnings And Dividend Update?

National Health Investors (NHI) recently reported higher Q2 2026 revenue and net income, along with a small dividend increase to $0.94 per share. While its 3-year shareholder return is strong, recent performance has been mixed. The company is considered 14.6% undervalued with an implied …

SouthState’s New Government Contractor Banking Push Might Change The Case For Investing In SSB

SouthState Bank has expanded into Government Contractor Banking, appointing David Mathis to lead this new vertical. While this move diversifies the bank's business offerings, the article emphasizes that it doesn't immediately alter the primary investment considerations of deposit costs and commercial real estate exposure …

Why Is American Healthcare REIT (AHR) Back On Investors’ Radar?

American Healthcare REIT (AHR) has garnered renewed investor interest following strong Q2 results, increased revenue and net income, and raised full-year earnings guidance for 2026. Despite a recent share price pullback, the stock has delivered significant year-to-date and one-year returns. While some analyses suggest …

TherapeuticsMD, Inc. Revenue Breakdown – NASDAQ:TXMD

This article provides a revenue breakdown for TherapeuticsMD, Inc. (NASDAQ: TXMD), highlighting that the greatest contribution to its revenue came from the United States, accounting for $1.79 million USD last year and $1.12 million USD the year prior. The data is presented through TradingView, …

Travelers Companies (TRV) Q2 Profit Rebound Puts Its Valuation Back In Focus

Travelers Companies (TRV) reported a strong Q2 2026 profit rebound driven by lower catastrophe losses and higher investment income, leading to an 8.2% share price increase and a 39% one-year total shareholder return. Despite this, a common valuation model suggests TRV is about 4% …

Northern Trust expands First Sentier mandate for $14B Irish fund structure

* Northern Trust Corporation (NTRS [https://seekingalpha.com/symbol/NTRS]) expanded [https://seekingalpha.com/pr/20624978-northern-trust-expands-relationship-with-first-sentier-group-to-support-irish-fund-structure] its relationship with First Sentier Group after being appointed fund administrator and depositary for the asset manager’s $14B Irish fund structure. * Under the mandate, Northern Trust Corporation (NTRS [https://seekingalpha.com/symbol/NTRS]) will provide custody, depositary, fund accounting, …

Cardinal Health CIO Greene sells $2.75m in stock

Michelle D. Greene, CIO of Cardinal Health Inc. (NASDAQ:CAH), sold 11,650 shares for $2.75 million on August 18, 2026, with transactions ranging from $234.07 to $237.32 per share. This sale follows a strong 55% return for Cardinal Health shares over the past year. The …

Black (BDTX) Results Versus Estimates: EPS Comes in Above Forecast for the Current Session; Share Response: The Share Price Adds 6.31% in Latest Trading - Profit Growth Outlook

Las acciones de Sherwin Williams (SHW) parecen sobrevaloradas y con un potencial alcista limitado

Die Aktie von Sherwin Williams (SHW) erscheint überbewertet und bietet nur begrenztes Aufwärtspotenzial

Fathom (FTHM) EPS and Revenue: Reported EPS Misses Expectations in the Latest Session; Market Response: The Stock Ends Up 0.84% on the Day - Low Growth Earnings

Galectin (GALT) Earnings Update: Profit Per Share Falls Below Its Benchmark in the Reported Period; Market Response

Universal Health Services (UHS) Q2 Earnings and Revenues Top Estimates

North Media Q2 2026: Financial results affected by expected volume decline

North Media A/S Selskabsmeddelelse nr. 13-2026 20 August 2026 Martin Frandsen Tobberup, Group CEO of North Media, on the Group's performance in Q2 2026: "Our financial results were affected by an expected volume decline in our distribution businesses. In the underlying business, we further …

Enterprise value to revenue forward of Hightide Therapeutics Inc – HKEX:2511

UBS raises Iovance Biotherapeutics stock price target on revenue beat

Toll Brothers (TOL) Could Be 7% Undervalued Following Earnings Beat And Reaffirmed Guidance

Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. Toll Brothers (TOL) stock came into focus after the builder reported third quarter results that topped analyst forecasts for revenue and earnings per …

The Bull Case For PTC Therapeutics (PTCT) Could Change Following Renal Data Progress For ST-920

PTC Therapeutics recently discussed the positive regulatory progress of ST-920, supported by Phase 1/2 STAAR data showing significant renal benefits and a favorable safety profile. This development could reshape the company's investment narrative and pipeline, diversifying beyond its current commercial base. While PTC Therapeutics …

131,800 Shares in Healthcare Services Group, Inc. $HCSG Bought by Lisanti Capital Growth LLC

Lisanti Capital Growth LLC recently acquired a new stake of 131,800 shares in Healthcare Services Group, Inc. (NASDAQ:HCSG), valued at approximately $3.24 million. Other institutional investors also adjusted their positions in the company, which saw its stock rise by 4.5%. Healthcare Services Group reported …